We have found excellent overall concordance between a point-of-care mRNA assay, STRAT4, and immunohistochemistry for breast cancer biomarker evaluation for ER and HER2 for 150 samples fixed and processed in Rwanda. This evidence concerns the gene ESR1 and breast carcinoma.